Astrazeneca Stock News

ARCH, AZN, and AXTA have been added to the Zacks Rank #5 (Strong Sell) List on February 4, 2022

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.

AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a cardiovascular drug. Get the Inside Access Traders Are Using to Profit More and Win

Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Biobanking Market 2021-2027" report has been added to ResearchAndMarkets.com''s offering. The biobanking market is anticipated to grow at a substantial CAGR of 6.7% during the forecast period. The market is set to display impressive growth during the forecast period with some key trends emerging, such as the need of tackling the increasing prevalence of cancers and chronic diseases driven by continuously evolving end-user expectations. The biobanking market is focused on the production and refurbishment of technologically advanced devices within time constraints by carrying out several types of research. It also depends on the level of inventory management practices of OEM and MRO clients. The growth in the R&D investments, government initiatives, and policies to reduce the prevalence of several diseases and the increase in awareness about stem cell therapies are some of the opportunities for the market players in the forecast period. Further, the high focus on automation and issues related to biospecimen sample procurement are the factors that are restraining the market growth during the forecast period.

Global stocks that are worth holding for the long-term for a well diversified portfolio. High growth global stocks with strong fundamentals.

APPN, AZN, and GRWG have been added to the Zacks Rank #5 (Strong Sell) List on January 25, 2022

A booster dose of AstraZeneca (AZN), Pfizer (PFE)/ BioNTech (BNTX), and Johnson & Johnson (JNJ) vaccines led to a significant increase in COVID-19 antibody levels in those who

A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or Johnson & Johnson (NYSE: JNJ) increases antibody l

All of them have tremendous growth prospects.

AstraZeneca has begun making decent profits with the COVID vaccine. Although other vaccine makers have made huge profits, AZN hasn't done too badly either despite its non-profit stance earlier.

These bear market stocks provide capital protection in a sharp correction scenario. They also typically have a healthy dividend yield.

South African Scientists Confirm Boosters Offer Little Protection From Omicron On Monday, a team of Israeli scientists publicized research showing that even a second booster dose of the Moderna or Pfizer mRNA vaccines doesn''t bestow complete immunity from the omicron variant. Now, just days later, their conclusion appears to have been corroborated by a team of South African researchers from the University of Cape Town and Stellenbosch University who observed seven individuals who had been infected with the omicron variant despite having been "boosted". The patients represented the first known cases of breakthrough infection by omicron, the researchers told the Lancet , the British medical journal where their findings were published. Keep in mind, the South African team used a very different approach. First of all, the patients they examined had only received a single booster dose (unlike with the Israeli study, which focused on patients who had received two doses). As for the study''s subjects, all of them were white, and four were participating in medical training at Cape Town hospitals.

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable hepatocellular carcinoma compared with soraf

AstraZeneca PLC (LSE:AZN) its drug Imfinzi plus chemotherapy reduced the risk of death by 20% in people with advanced biliary tract cancer (BTC). The results emerged from the Anglo-Swedish giant's TOP

The combination of AstraZeneca Imfinzi (durvalumab) + the company experimental CTLA-4 inhibitor tremelimumab led to a clinically meaningful improvement in overall survival.